LOXO-305 is an investigational drug.
There have been 26 clinical trials for LOXO-305.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 9th 2021.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Loxo Oncology, Inc., Eli Lilly and Company, and M.D. Anderson Cancer Center.
There are four US patents protecting this investigational drug and sixty-two international patents.